FierceBiotechOriginal article
{"a":[{"_":"Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial","$":{"href":"/biotech/sling-reels-123m-series-c-funding-its-oral-tepezza-rival-eye-disease","hreflang":"en"}}]}
Sling oral therapyPositive
AI Analysis
Summary
Sling Therapeutics closed a $123 million Series C funding round to advance its oral therapy for thyroid eye disease through Phase 3 testing and toward commercialization.
Clinical Trial Data
Phase
3
Importance:6/10
Sentiment:
0.60
fundingseries_cphase_3thyroid_eye_diseaseoral_therapy
Read the original article
Published by FierceBiotech on September 15, 2026 4:12 PM
